Select your Market
-
{{ userContent.title }}
{{ userContent.lookingForMoreLabel }}
OVERVIEW AND OUTLOOK
Overview of Q3 2020
- Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with Biogen Inc.
- Life Science grows organically by 15.6%, mainly thanks to the Process Solutions business
- Mavenclad and Bavencio drive organic growth of Healthcare; recovery in the Fertility franchise
- Semiconductor Solutions business of Performance Materials grows organically by 8.0%
Outlook for fiscal 2020
- Company expects organic sales growth of 4% to 5% over the previous year and Group net sales of between € 17.1 billion and € 17.5 billion
- Organic growth of EBITDA pre over the previous year excluding provision release between 6% and 8% expected, EBITDA pre in a range between € 5.05 billion and € 5.25 billion
The superb results of the third quarter once again underscore the strength of our diversified business model.
ADDITIONAL INFORMATION
Financial Report
Downloads for the Media
Additional Downloads
- Presentation for Analysts (PDF)
- Financial Statement (XLS)
- Financial Statement (PDF)
- Regional Sector Sales (XLS)
- Summary (PDF)
Annual Reports Archive
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Quarterly Statement
Q3 2020
Merck KGaA, Darmstadt, Germany grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, Reports Strong Third Quarter
Merck KGaA, Darmstadt, Germany, grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
2020/11/12